G. Manikhas

Significantly Longer Progression-Free Survival With <i>nab</i>-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

William J. Gradishar, D. Krasnojon, Sergey Cheporov et al. · Journal of Clinical Oncology · 2009 · 343 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

William J. Gradishar, D. Krasnojon, Sergey Cheporov et al. · Clinical Breast Cancer · 2012 · 122 citations

Medicine, Oncology, Pharmacology +11

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Marc Peeters, A. H. Strickland, Mikhail Lichinitser et al. · British Journal of Cancer · 2013 · 79 citations · Full text

Medicine, Oncology, Pharmacology +10

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Mark A. Socinski, G. Manikhas, Daniil Stroyakovsky et al. · Journal of Thoracic Oncology · 2010 · 77 citations · Full text

Medicine, Oncology, Pharmacology +15

Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC

W. Brugger, Nadja Triller, Maria Błasińska-Morawiec et al. · Journal of Clinical Oncology · 2009 · 57 citations

Medicine, Oncology, Pharmacology +17